Billy Kelleher
Ceist:115. Deputy Billy Kelleher asked the Minister for Health the specific thresholds, parameters or guidelines in place to gauge and measure the cost effectiveness of new drugs and medications. [8321/15]
Amharc ar fhreagraWednesday, 25 February 2015
Ceisteanna (115)
Freagraí scríofa
Under the terms of the 2012 Agreement between the Department of Health, the HSE and the Irish Pharmaceutical Healthcare Association, the HSE has the right to assess new and existing technologies that may be a high cost or have a significant budget impact on the Irish healthcare system or to determine the cost effectiveness of products from time to time.
In accordance with the Agreement a Health Technology Assessment may be carried out on new drugs or medicines by the National Centre for Pharmacoeconomics. As part of the pharmacoeconomic assessment a cost effectiveness threshold of €45,000 per quality adjusted life year is applied.